Statement from the CEO and the Board of Directors of Mithra following the articles published in the Belgian press
Following publications in the press on Wednesday, 22 January 2020 regarding an alleged insider trading offence attributed to Mr. François Fornieri, CEO of Mithra Pharmaceuticals, Mr. Fornieri vigorously contests any involvement in any such offence and deeply regrets the prejudice caused by this alleged information to Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health.
"I vehemently deny that I would have committed an offence and would have given any inside information to anyone outside of Mithra. I deeply regret the impact that these media releases have had on Mithra, a rapidly developing listed company, and that violate the confidentiality of the investigation. I am available to answer any questions in all transparency that the competent authorities may have. Let them do their investigative work without any further disruption", says François Fornieri.
The Board of Directors of Mithra, chaired by Marc Coucke, also reacted "by reiterating its full confidence in its CEO and expressly asking him to continue his mission as CEO and to carry out the group's strategy as always. The members of our Board of Directors reaffirm their full commitment to Mithra, one of Belgium's leading biotech companies, and their firm determination to scrupulously follow good governance practices".
About Mithra
Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women’s Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra’s goal is to develop products offering better efficacy, safety and convenience, meeting women’s needs throughout their life span. Its three lead development candidates are built on Mithra’s unique native estrogen platform, Estetrol (E4): Estelle®, a new era in oral contraception, PeriNesta®, the first complete oral treatment for perimenopause and Donesta®, the next-generation hormone therapy. Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 85 countries around the world, Mithra has an approximate headcount of 250 staff members and is headquartered in Liège, Belgium. www.mithra.com